Production Featured Articles

  1. Do Strategic Partnerships Meet Outsourcers Expectations? 10/18/2021

    ISR’s CDMO Outsourcing Models report dives into three approaches to contracting manufacturing work, the motivations behind using each approach, and details on which methods earn the greatest satisfaction among users.

  2. COVID-19 Spurs Growth Of China’s Domestic Bioprocessing Suppliers 10/8/2021

    Just as the U.S. and European bioprocessing supply systems have seen more robust growth than ever before, China’s domestic demands for single-use bags, cell culture media, and purification resins are all on the rise. BioPlan’s Top1000Bio database of global bioprocessing facilities has tracked industry capacity and employment growth over 15 years. 

  3. Unified Capabilities To Support Your Product Development Journey 10/4/2021

    Through a breadth of facilities, resources, and experience, Grace’s FCMS can serve customers’ needs from coast to coast, ensuring supply chain efficiency, safety, and security throughout the product development journey.

  4. The Importance Of CMC Developability Assessments: A Conversation With AltruBio’s Dr. Gene Lee 10/4/2021

    Dr. Gene Lee, Vice President of Technical Development at AltruBio, sat down to discuss getting the developability question right and why it’s important to understand your end game as early as discovery.

  5. Must-Use Strategies To Successfully Transfer And Scale Your Pharmaceutical Product 10/4/2021

    Finding the best commercial partner for your program starts with obtaining mission-critical technical capabilities. The best place to begin a serious conversation about the firm’s true potential to provide that value should start with a dialogue about the technology transfer process.

  6. The Importance Of CDMO Capacity For Viral Vectors: A Conversation With Forge’s Dr. Timothy Miller 10/4/2021

    In this episode of The Business of Biotech, Forge Biologics' Dr. Timothy Miller talks about the importance of increasing specialized CDMO capacity for cell and gene therapy applications.

  7. FMEA Vs. System Risk Structures (SRS): Which Is More Useful? 9/24/2021

    In this article, Mark Witcher, Ph.D., discusses the many failure modes of FMEA and risk priority number (RPN), comparing and contrasting it with system risk structures (SRS) and adjusted risk likelihood (RPN). He concludes that one of these is more useful than the other for pharma and medical devices; which one is it?

  8. Key Productivity, Scalability Considerations 9/21/2021

    COVID-19 caused biopharma innovators, CDMOs, data management firms, and raw material suppliers to collaborate at a level never seen before. How do we maintain that collaborative spirit under duress?

  9. How Digitization Is Delivering Competitive Advantage In Device Assembly 9/20/2021

    Data and the digitization of assembly equipment work together to deliver competitive advantage to pharma partners in terms of product quality, continuous improvement, de-risking maintenance and change management, and the ability to deliver unique identities and traceability for every assembled device.

  10. How Modularity Is A Clear Winner When It Comes To Flexibility And Scalability In Drug Delivery Device Assembly 9/20/2021

    How can machine vendors meet customer requirements and streamline drug delivery device assembly from the prototyping phase up to commercialization? The answer is modularity.